Weekly Investment Analysts’ Ratings Changes for AEterna Zentaris (AEZS)

AEterna Zentaris (NASDAQ: AEZS) recently received a number of ratings updates from brokerages and research firms:

  • 1/26/2018 – AEterna Zentaris was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.50 price target on the stock. According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
  • 1/17/2018 – AEterna Zentaris was given a new $4.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 1/16/2018 – AEterna Zentaris was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.50 price target on the stock. According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
  • 1/15/2018 – AEterna Zentaris was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
  • 12/21/2017 – AEterna Zentaris was given a new $4.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) opened at $2.39 on Monday. The stock has a market capitalization of $39.11, a P/E ratio of -1.32 and a beta of 0.87. AEterna Zentaris Inc. has a 12-month low of $0.78 and a 12-month high of $3.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). AEterna Zentaris had a negative return on equity of 732.74% and a negative net margin of 2,338.61%. The company had revenue of $0.24 million for the quarter. analysts anticipate that AEterna Zentaris Inc. will post -1.5 earnings per share for the current fiscal year.

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply